Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 449

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 449
---
 the Endeavor Argentina Regional Board of Directors from 2015 to 2022, president of the Latin American Association of Private Clinical Laboratories since 2010 and director of Medicina Esencial, a regional health management organization since 2003. He also served as the director of ACLIRES LAB from 2007 to 2011 where he was dedicated to phase 1 clinical trials, director of Sanatorio Parque and the Sanatorio de Niños Lab from 1992 until 2004, director of the Center of Molecular Diagnostics in BioSidus from 1995 to 2001 and director and President of CIBIC Laboratories since 1990. Mr. Fay has actively overseen laboratory operations for local, regional and central laboratories for over 20 clinical trials between 1994 and 2015. Mr. Fay also has extensive experience in the introduction of diagnostic technology in Argentina and Latin America. In addition, he was an ad -honoremconsultant for a COVID program with the state of Santa Fe from 2020 until 2023 and has been an ad -honoremconsultant for HIV and Hepatitis National Health Programs with the Argentinean Health Ministry since 2005. Mr. Fay was also an Invited Professor for several post -graduatecourses since 2005 and a member of the Expert Committee on Viral Hepatitis for the Argentinean Association of Liver Diseases. Mr. Fay is a biochemist with a degree from the National University of Rosario, with a post -graduatedegree in clinical pharmacology from the National University of Buenos Aires from 2002. Natalia Zang.Upon the Closing of the Business Combination, Ms. Zang is expected to serve as non -executivedirector of the Company. Ms. Zang is a business leader with more than 28 years of experience in private equity, venture capital and corporate finance in Latin America, Europe and Australia. Ms. Zang has served as a Bioceres Crop Solutions Corp. non -executivedirector since March 2019. She also serves as a non -executivedirector of Moolec Science SA, chair of the audit and compensation committee. She currently advises Gameto, a women -ledbiotech company developing treatment solutions to improve women’s reproductive health. She served as the COO of Jazzya Investments, member of the investment committee of MBV Fund and CFO of Overture Life a biotech company focused on automating procedures for embryology. Previously, Ms. Z